EpiBiologics closed a $107 million Series B to advance its EpiTAC protein‑degrader antibody platform and prepare its lead candidate EPI‑326 for first‑in‑human testing. The Bay Area company positioned EPI‑326 for non‑small cell lung cancer and head‑and‑neck indications and highlighted a safety profile that could enable combination therapies. Investors including GV and J&J’s corporate venture arm participated. Management said human testing would begin in H1 2026 and that the financing supports multiple additional discovery programs combining degradation and ADC modalities.